Trial
NCT06419166
An Exploratory Clinical Study of GC012F Injection for Refractory gMG
Early Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Zhejiang University
Collaborators
Gracell Biotechnologies (Shanghai) Co., Ltd.
Condition
Refractory Generalized Myasthenia Gravis
Intervention
GC012F injection
Why stopped
The study stopped early, before enrolling its first participant.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-27